Insulin Secretion Curve – Phases and Clinical Relevance

What Is the Insulin Secretion Curve?

The insulin secretion curve describes the time course of insulin release by the beta cells of the pancreas. It graphically illustrates how much insulin is secreted into the bloodstream at any given point in time – typically in response to a rise in blood glucose levels, such as after eating.

Analyzing this curve provides important information about pancreatic function and is used in diabetology to detect disturbances in insulin production at an early stage.

Physiological Course of Insulin Secretion

Under normal conditions, insulin secretion follows two characteristic phases:

• First phase (early phase): Immediately after a rise in blood glucose – approximately 1 to 3 minutes after glucose intake – a pre-stored amount of insulin is rapidly released. This phase lasts about 5 to 10 minutes and results in a sharp spike in blood insulin concentration.
• Second phase (late phase): If elevated blood glucose persists, a second, more sustained wave of insulin secretion follows. This phase begins after approximately 10 minutes and can last 60 to 120 minutes, during which newly synthesized insulin is released until blood glucose returns to normal.

In addition, there is a continuous basal insulin secretion that occurs independently of meals to meet the body's baseline energy requirements.

Clinical Relevance

The insulin secretion curve is diagnostically significant, particularly in the evaluation of diabetes mellitus and related metabolic disorders:

• Type 1 diabetes: The beta cells are destroyed by the immune system. The insulin secretion curve shows markedly reduced or completely absent insulin release in both phases.
• Type 2 diabetes: The first phase of insulin secretion is typically blunted or delayed, leading to a slower postprandial blood glucose decline. As the disease progresses, the second phase also diminishes.
• Prediabetes: Even before fasting blood glucose becomes abnormal, a loss of the early-phase insulin secretion can be observed in the prediabetic state.
• Insulinoma: An insulin-producing tumor of the pancreas leads to excessively high and unregulated insulin secretion, visible in the curve as a persistently elevated insulin level.

Measurement and Diagnostics

The insulin secretion curve is typically measured during an oral glucose tolerance test (OGTT) or an intravenous glucose tolerance test (IVGTT). Blood samples are taken at defined time points, and both blood glucose and serum insulin concentrations are measured.

• Oral Glucose Tolerance Test (OGTT): The patient drinks a defined glucose solution (usually 75 g of glucose). Blood glucose and insulin levels are measured in the fasting state and at 30, 60, 90, and 120 minutes after ingestion.
• Intravenous Glucose Tolerance Test (IVGTT): Glucose is injected directly into a vein. This method allows more precise assessment of the early secretion phase, as gastric emptying is eliminated as a confounding factor.
• C-peptide measurement: Since C-peptide is cleaved from the insulin precursor proinsulin in equimolar amounts, its concentration serves as an indirect marker of endogenous insulin production – particularly relevant in patients already receiving exogenous insulin.

Factors Influencing the Insulin Secretion Curve

Various factors can affect the shape of the insulin secretion curve:

• Type of meal: Carbohydrate-rich meals lead to a faster and stronger insulin response compared to fat- or protein-rich meals.
• Glycemic index: Foods with a high glycemic index cause rapid blood glucose spikes and stimulate a stronger insulin release.
• Body weight and insulin resistance: In overweight individuals and those with insulin resistance, the pancreas must produce more insulin to achieve the same blood glucose-lowering effect.
• Medications: Certain antidiabetic drugs such as sulfonylureas or GLP-1 receptor agonists specifically modify the insulin secretion curve.
• Age: The capacity of beta cells for rapid insulin release tends to decline with increasing age.

Relevance for Therapy

Understanding the insulin secretion curve is essential for individualized diabetes therapy planning. Modern insulin regimens aim to replicate the physiological secretion pattern as closely as possible:

• Basal insulin covers the continuous background requirement, mirroring basal secretion.
• Bolus insulin (rapid-acting insulin) is administered at mealtimes to replace the meal-induced insulin surge.
• Advanced delivery systems such as insulin pumps or closed-loop systems (also called artificial pancreas systems) allow even more precise adaptation to the natural insulin secretion profile.

References

1. Kasper, D. L. et al. (Eds.) – Harrison's Principles of Internal Medicine, 21st Edition, McGraw-Hill Education, 2022.
2. American Diabetes Association – Standards of Medical Care in Diabetes 2024. Diabetes Care, 47 (Suppl. 1), 2024. Available at: https://diabetesjournals.org/care
3. Stumvoll, M., Goldstein, B. J., van Haeften, T. W. – Type 2 diabetes: principles of pathogenesis and therapy. The Lancet, 365(9467), 1333–1346, 2005. Available at: https://www.thelancet.com